India-made Covaxin showed 81 percent interim efficacy - Bharat Biotech on Phase 3 results - Android

New Delhi, Mar 03: Bharat Biotech's coronavirus vaccine - Covaxin has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Hyderabad-based company said on Wednesday. "Covaxin demonstrated 81% interim efficacy in preventing Covid-19 in those without prior infection